Search

Your search keyword '"Dougan, Michael"' showing total 1,068 results
Start Over Author "Dougan, Michael"
1,068 results on '"Dougan, Michael"'

1. AGuIX nanoparticle-nanobody bioconjugates to target immune checkpoint receptors

Author

Carmès, Léna, Bort, Guillaume, Lux, François, Seban, Léa, Rocchi, Paul, Muradova, Zeinaf, Hagège, Agnès, Heinrich-Balard, Laurence, Delolme, Frédéric, Gueguen-Chaignon, Virginie, Truillet, Charles, Crowley, Stephanie, Bello, Elisa, Doussineau, Tristan, Dougan, Michael, Tillement, Olivier, Schoenfeld, Jonathan, Brown, Needa, and Berbeco, Ross

Subjects
Physics - Biological Physics
Abstract

Comparison of click chemistry and sortagging grafting strategies for functionalizing AGuIX nanoparticles with nanobodies to develop a tri-functional technology combining MRI imaging, radiotherapy, and immunotherapy by inhibiting immune checkpoints., Comment: Nanoscale, 2024

Published
2024
Full Text
View/download PDF

3. Single-cell transcriptomic analyses reveal distinct immune cell contributions to epithelial barrier dysfunction in checkpoint inhibitor colitis

Author

Thomas, Molly Fisher, Slowikowski, Kamil, Manakongtreecheep, Kasidet, Sen, Pritha, Samanta, Nandini, Tantivit, Jessica, Nasrallah, Mazen, Zubiri, Leyre, Smith, Neal P., Tirard, Alice, Ramesh, Swetha, Arnold, Benjamin Y., Nieman, Linda T., Chen, Jonathan H., Eisenhaure, Thomas, Pelka, Karin, Song, Yuhui, Xu, Katherine H., Jorgji, Vjola, Pinto, Christopher J., Sharova, Tatyana, Glasser, Rachel, Chan, PuiYee, Sullivan, Ryan J., Khalili, Hamed, Juric, Dejan, Boland, Genevieve M., Dougan, Michael, Hacohen, Nir, Li, Bo, Reynolds, Kerry L., and Villani, Alexandra-Chloé

Published
2024
Full Text
View/download PDF

4. Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Intravenous Infusions of PF-07304814 (Lufotrelvir) in Participants Hospitalized With COVID-19.

Author

Robinson, Philip, Toussi, Sima, Aggarwal, Sudeepta, Bergman, Arthur, Zhu, Tong, Hackman, Frances, Sathish, Jean, Updyke, Lawrence, Loudon, Peter, Krishna, Ganesh, Clevenbergh, Philippe, Hernandez-Mora, Miguel, Cisneros Herreros, Jose, Dougan, Michael, Thacker, Amber, Baniecki, Mary, Soares, Holly, Whitlock, Mark, Nucci, Gianluca, Menon, Sandeep, Anderson, Annaliesa, Binks, Michael, and Albertson, Timothy

Subjects
COVID-19, PF-00835231, PF-07304814, SARS-CoV-2, antiviral
Abstract

BACKGROUND: An urgent need remains for antiviral therapies to treat patients hospitalized with COVID-19. PF-07304814-the prodrug (lufotrelvir) and its active moiety (PF-00835231)-is a potent inhibitor of the SARS-CoV-2 3CL protease. METHOD: Eligible participants were 18 to 79 years old and hospitalized with confirmed COVID-19. This first-in-human phase 1b study was designed with 2 groups: single ascending dose (SAD) and multiple ascending dose (MAD). Participants could receive local standard-of-care therapy. In SAD, participants were randomized to receive a 24-hour infusion of lufotrelvir/placebo. In MAD, participants were randomized to receive a 120-hour infusion of lufotrelvir/placebo. The primary endpoint was to assess the safety and tolerability of lufotrelvir. The secondary endpoint was to evaluate the pharmacokinetics of lufotrelvir and PF-00835231. RESULTS: In SAD, participants were randomized to receive 250 mg lufotrelvir (n = 2), 500 mg lufotrelvir (n = 2), or placebo (n = 4) by continuous 24-hour infusion. In MAD, participants were randomized to receive 250 mg lufotrelvir (n = 7), 500 mg lufotrelvir (n = 6), or placebo (n = 4) by continuous 120-hour infusion. No adverse events or serious adverse events were considered related to lufotrelvir. At doses of 250 and 500 mg, concentrations for the prodrug lufotrelvir and active moiety PF-00835231 increased in a dose-related manner. Unbound concentrations of the lufotrelvir active metabolite reached steady state approximately 2- and 4-fold that of in vitro EC90 following 250- and 500-mg doses, respectively. CONCLUSIONS: These safety and pharmacokinetic findings support the continued evaluation of lufotrelvir in clinical studies. Clinical Trials Registration. ClinicalTrials.gov NCT04535167.

Published
2023

5. Concurrent immune checkpoint inhibition and selective immunosuppressive therapy in patients with immune-related enterocolitis.

Author

Badran, Yousef R, Zou, Fangwen, Durbin, Sienna M, Dutra, Barbara E, Abu-Sbeih, Hamzah, Thomas, Anusha S, Altan, Mehmet, Thompson, John A, Qiao, Wei, Leet, Donna E, Lai, Po-Ying, Horick, Nora K, Postow, Michael A, Faleck, David M, Wang, Yinghong, and Dougan, Michael

Subjects
Humans, Enterocolitis, Retrospective Studies, Infliximab, Antineoplastic Agents, Immunological, Immune Checkpoint Inhibitors, Immunosuppression Therapy, Autoimmunity, Immunotherapy, Inflammation, Digestive Diseases, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals
Abstract

PurposeImmune checkpoint inhibitor (ICI) therapy is often suspended because of immune-related enterocolitis (irEC). We examined the effect of resumption of ICIs with or without concurrent selective immunosuppressive therapy (SIT) on rates of symptom recurrence and survival outcomes.MethodsThis retrospective, multicenter study examined patients who were treated with ICI and developed irEC requiring SIT (infliximab or vedolizumab) for initial symptom control or to facilitate steroid tapering between May 2015 and June 2020. After symptom resolution, patients were restarted either on ICI alone or on concurrent ICI and SIT at the discretion of the treating physicians. The associations between irEC recurrence and treatment group were assessed via univariate analyses and multivariate logistic regression. Cox proportional hazards model was used for survival analysis.ResultsOf the 138 included patients who required SIT for initial irEC symptom control, 61 (44.2%) patients resumed ICI without concurrent SIT (control group) and 77 (55.8%) patients resumed ICI therapy with concurrent SIT: 33 with infliximab and 44 with vedolizumab. After symptom resolution, patients in the control group were more commonly restarted on a different ICI regimen (65.6%) compared with those receiving SIT (31.2%) (p

Published
2023

7. Recombinant GM-CSF for diseases of GM-CSF insufficiency: Correcting dysfunctional mononuclear phagocyte disorders

Author

Lazarus, Hillard M, Pitts, Katherine, Wang, Tisha, Lee, Elinor, Buchbinder, Elizabeth, Dougan, Michael, Armstrong, David G, Paine, Robert, Ragsdale, Carolyn E, Boyd, Timothy, Rock, Edwin P, and Gale, Robert Peter

Subjects
Biomedical and Clinical Sciences, Immunology, Autoimmune Disease, Vaccine Related, Immunotherapy, Immunization, Development of treatments and therapeutic interventions, 5.1 Pharmaceuticals, Humans, Granulocyte-Macrophage Colony-Stimulating Factor, Immune Checkpoint Inhibitors, COVID-19, Macrophages, Monocytes, mononuclear phagocyte, sargramostim, immunomodulation, granulocyte-macrophage colony-stimulating factor, autoimmune pulmonary alveolar proteinosis, wound healing, immune checkpoint inhibitors, Medical Microbiology, Biochemistry and cell biology, Genetics
Abstract

IntroductionEndogenous granulocyte-macrophage colony-stimulating factor (GM-CSF), identified by its ability to support differentiation of hematopoietic cells into several types of myeloid cells, is now known to support maturation and maintain the metabolic capacity of mononuclear phagocytes including monocytes, macrophages, and dendritic cells. These cells sense and attack potential pathogens, present antigens to adaptive immune cells, and recruit other immune cells. Recombinant human (rhu) GM-CSF (e.g., sargramostim [glycosylated, yeast-derived rhu GM-CSF]) has immune modulating properties and can restore the normal function of mononuclear phagocytes rendered dysfunctional by deficient or insufficient endogenous GM-CSF.MethodsWe reviewed the emerging biologic and cellular effects of GM-CSF. Experts in clinical disease areas caused by deficient or insufficient endogenous GM-CSF examined the role of GM-CSF in mononuclear phagocyte disorders including autoimmune pulmonary alveolar proteinosis (aPAP), diverse infections (including COVID-19), wound healing, and anti-cancer immune checkpoint inhibitor therapy.ResultsWe discuss emerging data for GM-CSF biology including the positive effects on mitochondrial function and cell metabolism, augmentation of phagocytosis and efferocytosis, and immune cell modulation. We further address how giving exogenous rhu GM-CSF may control or treat mononuclear phagocyte dysfunction disorders caused or exacerbated by GM-CSF deficiency or insufficiency. We discuss how rhu GM-CSF may augment the anti-cancer effects of immune checkpoint inhibitor immunotherapy as well as ameliorate immune-related adverse events.DiscussionWe identify research gaps, opportunities, and the concept that rhu GM-CSF, by supporting and restoring the metabolic capacity and function of mononuclear phagocytes, can have significant therapeutic effects. rhu GM-CSF (e.g., sargramostim) might ameliorate multiple diseases of GM-CSF deficiency or insufficiency and address a high unmet medical need.

Published
2023

12. Novel endoscopic scoring system for immune mediated colitis: a multicenter retrospective study of 674 patients

Author

Wang, Yinghong, Abu-Sbeih, Hamzah, Tang, Tenglong, Shatila, Malek, Faleck, David, Harris, Jessica, Dougan, Michael, Olsson-Brown, Anna, Johnson, Douglas B., Shi, Chanjuan, Grivas, Petros, Diamantopoulos, Leonidas, Owen, Dwight H., Cassol, Clarissa, Arnold, Christina A., Warner, David E., Alva, Ajjai, Powell, Nick, Ibraheim, Hajir, De Toni, Enrico N., Philipp, Alexander B., Philpott, Jessica, Sleiman, Joseph, Lythgoe, Mark, Daniels, Ella, Sandhu, Shahneen, Weppler, Alison M., Buckle, Andrew, Pinato, David J., Thomas, Anusha, and Qiao, Wei

Published
2024
Full Text
View/download PDF

13. Guidance on mucositis assessment from the MASCC Mucositis Study Group and ISOO: an international Delphi study

Author

Laheij, Alexa, Tonkaboni, Arghavan, Scott, Jacqui, Abasaeed, Rania, Kauzman, Adel, Flato, Adriana Do Socorro Lima, Gore, Adwaita, Hardman, Anne-Marie, Horvath, Agnes, Hovan, Allan, Al-Jamaei, Aisha, koizumi, Aya, Santos-Silva, Alan, Majorana, Alessandra, Giannini, Alexandre, Teixeira, Aléxia, Shazib, Muhammad Ali, Melvin, Alison, Filho, Aluísio Miranda, Gruza, Amanda, Brown-Dahl, Amber, Harilall, Amit, El Maghrabi, Amr, Rogulj, Ana Andabak, Curvo, Ana Raphaela, Soares, Ana Laura, Stringer, Andrea, Moreira, Andréa, Kurtzweil, Andy, Salaberry, Angelyn, Blazy, Anne, Gussgard, Anne Margrete, Lynge Pedersen, Anne Marie, Freidank, Annette, Ariyawardana, Anura, Ramseier, Adrian, Arends, Jann, Blanchard, Ariel, Paz, Adriana Sesti, Thermann, Angela, Poropat, Augusto, Freites-Martinez, Azael, Al-Azri, Abdul Rahman, Herlofson, Bente Brokstad, BalajiSubramanian, Sitaraman, Ballantyne, Barbara, Bektas-Kayhan, Kivanc, Hasséus, Bengt, Kaffenberger, Benjamin, Benites, Bernar, Kwong, Bernice, Test, Beth, Chiantia, Fernando, Pettersson, Bo, Framroze, Bomi, Bonomo, Pierluigi, Brzak, Božana Lončar, Dulmage, Brittany, Buga, Sorin, Spekssnijder, Caroline, Brown, Carlton, Melo, Antonio Carlos Moura de, Ribeiro, Ana Carolina, Silva, Caroline, Fulop, Caroline, Anderson, Carryn, Flaitz, Catherine, Massoud, Cathy, Migliorati, Cesar, Gross, Callie, Gandini, Chiara, Loprinzi, Charles, de Mooij, Charlotte, Hong, Catherine, Choi, Ying Chu, Choy, Maria, Boers-Doets, Christine, Schmeel, Leonard, Nagano, Cibele, Franco, Maria Coeli, Subramaniam, Courtney, Patrick, Carolyn, Poh, Catherine, Neuenschwander, Cristina, Virgen, Cesar, Riesenbeck, Dorothea, Weaver, Dale, Goldemberg, Daniel Cohen, Sundaresan, Daniel, Nunes, Daniela, Perez, Danyel, Travassos, Daphine, Yang, David, Ribeiro, Daniela, Kolbinson, Dean, Buick, Deborah, Saunders, Deborah, De Bortolli, Juliane, Chugh, Deepika, Markstrom, Denise, Travassos, Denise, Weikel, Dianna, Galiti, Dimitra, Peiris, Dinusha, Djordjevic, Fedja, Singhai, Pankaj, Keefe, Dorothy, Peterson, Douglas, Fonseca, Douglas, Pon, Doreen, Kovalenko, Iuliia, Polonskaia, Aleksandra, Caldas, Rogério, Saganski, Kevin, Néri, Julia, Abbott, Dennis, Yergolkar, Abhijna Vithal, Del Conte, Cristina, Passos, Januaria, Uezu, Katia, Silva, Paula, Gilbert, Steven, Yeoh, Keng, Jain, Kunal, Rastogi, Madhup, Sankaran, Satheeshkumar Poolakkad, Manne, Deborah, Shatokhina, Evgeniya, Adebayo-Olojo, Esther, Somogyi-Ganss, Eszter, Ehrenpreis, Eli, Bernaola-Paredes, Wilber, Fregnani, Eduardo, Cardoso, Elaci, Bardellini, Elena, Arvanitou, Eleni, Fontes, Elisa Kauark, Bruning, Elise, Neumann, Eloise, Madureira, Elsa, Ramires, Marcia, Papadopoulou, Erofili, Munhoz, Etiene, Spijkervet, Fred, Granzotto, Fabiana, Martins, Fabiana, Alves, Fabio, Mougeot, Farah, Aielli, Federica, Pigatti, Fernanda, Fonseca, Fernanda, Samim, Firoozeh, Carvalho, Flavia, Zelaya, Florence Cuadra, Freytes, Cesar, da Silveira, Gabriela, Torino, Gabriela, Martins, Gabriela, Silva, Geisa, Caro, Gemma, Bryan, Gemma, Radford, Georgette, Al-Qadami, Ghanyah, Albini, Giorgia, Mainville, Gisele, Gkardiakos, Georgios, Potter, Gleidston, Hoeberechts, Gulbin, Howarth, Gordon, Ottaviani, Giulia, Bradley, Grace, Verma, Gunjan, Santos, Gustavo dos, Randles-Guzzardi, Margaret, Engelbrecht, Hanlie, Wardill, Hannah, Hansen, Heidi, Hasan, Iquebal, Hata, Hironobu, Ullgren, Helena, Antunes, Heliton Spindola, Laís dos Santos, Heloísa, Weld, Howard, McInnes, Helen, Jungbluth, Hans Peter, Weng, Hsiaofen, Hewson, Ian, Santos, Ingrid, Illarramendi, Jorge, Semendric, Ines, Menge, Rol, Von Bultzingslowen, Inger, Melo, Maria da Gloria de, Leong, Iona, Fonseca, Isabella, Kalif, Isadora, Carroll, James, Coller, Janet, Beck-Mannagetta, Johann, Bowen, Joanne, Meurer, Jose, McCullough, Ricky, Powers, Jennifer, Gomez, Jesus, Lenjisa, Jimma, jaya Vangara, Leko, Jasna, Fall-Dickson, Jane, Mougeot, Jean-Luc, Fox, Joan, Epstein, Joel, Robijns, Jolien, Wu, Jonn, Palma, Patricio, Amaram-Davila, Jaya, Siderov, Jim, Raber-Durlacher, Judith, Dantas, Juliana, Jasper, Juliana, Monteiro, Juliana, Bruno, Julia, julie pfeffer, Ristivojevic, Julija Jovanovic, Brito, Juliana, Kuriakose, Jyothsna, Kabasawa, Yuji, Dave, Kanan, Barczyszyn, Karin, Lima, Karol Sartori, Secombe, Kate, White, Kate, Cooper, Kate, Katsura, Kouji, Biggs, Karen, Ciarrocca, Katharine, Dennis, Kristopher, Tomizuka, Ken, Hendler, Kevin, Komo, Ikuko, Skallsjö, Kristina, Hodgins, Kristy, Rupel, Katia, Tanaka, Keiko, Kurup, Seema, Gueiros, Luiz, Agatti, Larissa, Garzona-Navas, Laura, Guerra, Letícia, Portela, Leila, Iossi, Leilani, Elting, Linda, Baad-Hansen, Lene, Reeder, Leslie, Lang, Leticia, Menezes, Liciane, Braun, Liliana, Grando, Liliane, Lim, Mathew, Fernandez, Lina, McKeage, Lucy, Campos, Luana, Simonato, Luciana, Muniz, Luciana, van Draanen, Leah, Mizutani, Mieko, Huang, Tsai-Wei, Riad, Mahfujul, Nazar, Mahnoor, Souza, Maíra, Minamisako, Mariana, Pereira, Manoela, Mantelato, Carlos, Diniz-Freitas, Márcio, Montezuma, Marco, Andrade, Marco, Santos, Marcos, Gobbo, Margherita, Fortuna, Maria Caterina, Vitor, Mariana, Marinho, Joana, Markova, Alina, Knuchel, Marlyse, Carlesimo, Marta, Neves, Marta, Mazar, Andrew, Gomez Amarilla, Maria Cristina, Chambers, Mark, Araujo, Melissa de, Melo, Alexandre, Cole, Melody, Elsayed, Mohamed, Fliedner, Monica, Hauer-Jensen, Martin, Bouchacourt, Micaela, Brennan, Michael, Thirlwell, Michael, Nakamura, Michio, Nakagaki, Midori, Rossi, Camila, Miller, Robert, Kaprilian, Mireille, Kase, Michael, Dougan, Michael, Stokman, Monique, Monsen, Ragnhild, Morgan, Alisha, Harding, Jocelyn, Taleghani, Maryam, Genot, Marie-Therese, Seshadri, Mukund, Muzyka, Brian, Batista, Nancy, Gadd, Nancy, Tanda, Naoko, Nasr, Narmin, Garcia, Natália, Lee, Nathan, Palmier, Natalia, Brito-Dellan, Norman, Corbitt, Nancy, Pieralisi, Neli, Serrano, Verônica, Iacovelli, Nicola Alessandro, Blijlevens, Nicole, Sampaio, Norma Lúcia, Karra, Nour, Venkatesh, Niveditha, Yarom, Noam, Borin, Renata Cristina, Lemenchick, Olivia, Mendes, Ondina, Nicolatou-Galitis, Ourania, Shchitka, Vasiliy, Bossi, Paolo, Reis, Paula, Santos, Paulo Sérgio, Fernandez-Ortega, Paz, Parker, Ira, García, Raquel, Fritz, Peter, Peters, Edmund, Gardner, Pamela, Girons, Pierre Saint, Tiwari, Priya, Chaturvedi, Pravin, de Moraes, Tais, Andrade, Priscila, Nair, Raj, Gibson, Rachel, Gururaj, Rachita, Abdalla-Aslan, Ragda, Thota, Raghu, Lalla, Rajesh, Mendes, Rui Amaral, Prado, Raquel Almeida, Ongole, Ravikiran, Taybos, George, Mackey, Regina, Rego, Renata, Camilotti, Renata, Ferrari, Renata, Junior, Renato, Bensadoun, Rene-Jean, Logan, Richard, Sales, Roberta, Zanicotti, Roberta, Tunes, Roberta, Mauceri, Rodolfo, Feitoza, Rosiene, Ruddy, Kathryn, Rybczyk, Cynthia, Trager, Stephanie, Mitsunaga, Sachiyo, Gunathilake, Sahani, Saini, Rajan, Salvestrini, Viola, Mukhopadhyay, Sandip, Angeloz, Sandrina, Sankar S, Pramod, Barbosa, Luciana S Barbosa, Volkova, Elena, Elad, Sharon, Cantoreggi, Sergio, Gordon, Sharon, Brown, Shelly, Janine Tam, Shu Yie, Faleiro, Sibelle, da Silva, Silmara, de Oliveira, Silvia, Jensen, Siri Beier, Skrinjar, Ivana, Beaumont, Sophie, Sperandio, Felipe, Reese, Sandra, Roser, Steven, Seo, Sachiko, van Leeuwen, Stephanie, Sonis, Stephen, Bernard, Stephen, Samuel, Stephen Rajan, Taylor, Stuart, Maitra, Suranjan, Skulski, Susanne, Carlisle, Suzanne, Avon, Sylvie Louise, Yokota, Tomoya, Yurikusa, Takashi, Polvora, Tabata Santos, Kelock, Tabitha, Fernandes, Tauana, Wain, Taylor, Brown, Timothy, Tetsuhito konishi, Ferreira, Thalyta Amanda, Kataoka, Tomoko, Kelly, Thomas, Mori, Takehiko, Higuchi, Tomoko, Saeki, Toshiaki, Tsoukalas, Nikolaos, De Vandeul, Typhaine Maupoint, Usubuchi, Masatoshi, Lacerda, Vanessa, Tilly, Vanessa, Vigarios, Emmanuelle, Villa, Alessandro, Torregrossa, Vinicius, Selvaraj, Vinodh Kumar, Sarmento, Viviane, Heng, Vivien, Gomes-Silva, Wagner, Kandwal, Abhishek, Wilberg, Petter, Miranda e Silva, Wanessa, I'zzah Wan Mohamad Zain, Wan Nor, Park, Wonse, Tissing, Wim, Soga, Yoshihiko, Van Sebille, Bella, Matsuda, Yuhei, Zadik, Yehuda, Cao, Katrina, Cheung, Yin Ting, Fregnani, Eduardo Rodrigues, Van Sebille, Ysabella, Kauark-Fontes, Elisa, McCurdy-Franks, Emma, Finkelstein, Joel, McCarvell, Victoria, Amaral Mendes, Rui, Speksnijder, Caroline Margina, and Wardill, Hannah Rose

Published
2024
Full Text
View/download PDF

16. Inhibition of CDK4/6 promotes CD8 T-cell memory formation

Author

Heckler, Max, Ali, Lestat R, Clancy-Thompson, Eleanor, Qiang, Li, Ventre, Katherine S, Lenehan, Patrick, Roehle, Kevin, Luoma, Adrienne, Boelaars, Kelly, Peters, Vera, McCreary, Julia, Boschert, Tamara, Wang, Eric S, Suo, Shengbao, Marangoni, Francesco, Mempel, Thorsten R, Long, Henry W, Wucherpfennig, Kai W, Dougan, Michael, Gray, Nathanael S, Yuan, Guo-Cheng, Goel, Shom, Tolaney, Sara M, and Dougan, Stephanie K

Subjects
Cancer, Breast Cancer, Development of treatments and therapeutic interventions, 5.1 Pharmaceuticals, Adult, Aged, Aminopyridines, Animals, Benzimidazoles, Breast Neoplasms, Breast Neoplasms, Male, CD8-Positive T-Lymphocytes, Cell Line, Tumor, Cyclin-Dependent Kinase 4, Cyclin-Dependent Kinase 6, Female, Humans, Male, Mice, Mice, Inbred C57BL, Middle Aged, Piperazines, Protein Kinase Inhibitors, Pyridines, Oncology and Carcinogenesis
Abstract

CDK4/6 inhibitors are approved to treat breast cancer and are in trials for other malignancies. We examined CDK4/6 inhibition in mouse and human CD8+ T cells during early stages of activation. Mice receiving tumor-specific CD8+ T cells treated with CDK4/6 inhibitors displayed increased T-cell persistence and immunologic memory. CDK4/6 inhibition upregulated MXD4, a negative regulator of MYC, in both mouse and human CD8+ T cells. Silencing of Mxd4 or Myc in mouse CD8+ T cells demonstrated the importance of this axis for memory formation. We used single-cell transcriptional profiling and T-cell receptor clonotype tracking to evaluate recently activated human CD8+ T cells in patients with breast cancer before and during treatment with either palbociclib or abemaciclib. CDK4/6 inhibitor therapy in humans increases the frequency of CD8+ memory precursors and downregulates their expression of MYC target genes, suggesting that CDK4/6 inhibitors in patients with cancer may augment long-term protective immunity. SIGNIFICANCE: CDK4/6 inhibition skews newly activated CD8+ T cells toward a memory phenotype in mice and humans with breast cancer. CDK4/6 inhibitors may have broad utility outside breast cancer, particularly in the neoadjuvant setting to augment CD8+ T-cell priming to tumor antigens prior to dosing with checkpoint blockade.This article is highlighted in the In This Issue feature, p. 2355.

Published
2021

20. Perspectives in immunotherapy: meeting report from the “Immunotherapy Bridge” (December 4th–5th, 2019, Naples, Italy)

Author

Ascierto, Paolo A, Butterfield, Lisa H, Campbell, Katie, Daniele, Bruno, Dougan, Michael, Emens, Leisha A, Formenti, Silvia, Janku, Filip, Khleif, Samir N, Kirchhoff, Tomas, Morabito, Alessandro, Najjar, Yana, Nathan, Paul, Odunsi, Kunle, Patnaik, Akash, Paulos, Chrystal M, Reinfeld, Bradley I, Skinner, Heath D, Timmerman, John, and Puzanov, Igor

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Immunology, Immunization, Vaccine Related, Cancer, Good Health and Well Being, Biomarkers, Tumor, Humans, Immunotherapy, Italy, Medical Oncology, Melanoma, Checkpoint inhibitors, Combination therapy, Biomarkers, Tumor microenvironment, Vaccine, Medical and Health Sciences, Biomedical and clinical sciences, Health sciences
Abstract

Over the last few years, numerous clinical trials and real-world experience have provided a large amount of evidence demonstrating the potential for long-term survival with immunotherapy agents across various malignancies, beginning with melanoma and extending to other tumours. The clinical success of immune checkpoint blockade has encouraged increasing development of other immunotherapies. It has been estimated that there are over 3000 immuno-oncology trials ongoing, targeting hundreds of disease and immune pathways. Evolving topics on cancer immunotherapy, including the state of the art of immunotherapy across various malignancies, were the focus of discussions at the Immunotherapy Bridge meeting (4-5 December, 2019, Naples, Italy), and are summarised in this report.

Published
2021

43. Abstract B016: Eosinophils alter metastatic spread in pancreatic cancer

Author

Hoffman, Megan T., primary, Lenehan, Patrick J., additional, Wang, Jen, additional, Ali, Lestat, additional, Uchida, Amiko, additional, Vayrynen, Sara, additional, Costa, Andressa Dias, additional, Dougan, Michael, additional, Heckler, Max, additional, Nowak, Jonathan, additional, Wolpin, Brian W., additional, and Dougan, Stephanie K., additional

Published
2024
Full Text
View/download PDF

44. AGuIX nanoparticle-nanobody bioconjugates to target immune checkpoint receptors

Author

Carmès, Léna, primary, Bort, Guillaume, additional, Lux, François, additional, Seban, Léa, additional, Rocchi, Paul, additional, Muradova, Zeinaf, additional, Hagège, Agnès, additional, Heinrich-Balard, Laurence, additional, Delolme, Frédéric, additional, Gueguen-Chaignon, Virginie, additional, Truillet, Charles, additional, Crowley, Stephanie, additional, Bello, Elisa, additional, Doussineau, Tristan, additional, Dougan, Michael, additional, Tillement, Olivier, additional, Schoenfeld, Jonathan D., additional, Brown, Needa, additional, and Berbeco, Ross, additional

Published
2024
Full Text
View/download PDF

48. Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of immune checkpoint inhibitor endocrinopathies and the role of advanced practice providers in the management of immune-mediated toxicities

Author

Cooksley, Tim, Girotra, Monica, Ginex, Pamela, Gordon, Ruth Ann, Anderson, Ronald, Blidner, Ada, Choi, Jennifer, Dougan, Michael, Glezerman, Ilya, Gupta, Dipti, Johnson, Douglas, Shannon, Vickie R., Suarez-Almazor, Maria, and Rapoport, Bernardo L.

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results